{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:48Z","timestamp":1790659248804,"version":"4.1.0"},"reference-count":188,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2025,3,4]]},"DOI":"10.1080\/13543784.2025.2473062","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:07:53Z","timestamp":1740722873000},"page":"169-195","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":30,"title":["The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists"],"prefix":"10.1080","volume":"34","author":[{"given":"Naim","family":"Alkhouri","sequence":"first","affiliation":[{"name":"Arizona Liver Health","place":["Phoenix, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Charlton","sequence":"additional","affiliation":[{"name":"University of Chicago Biological Sciences","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Gray","sequence":"additional","affiliation":[{"name":"The University of Alabama at Birmingham","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[{"name":"Houston Research Institute","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00020-0"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.052"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14018"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.006"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17997"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1424155"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.24106"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000488"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.24069"},{"key":"e_1_3_7_16_1","unstructured":"Madrigal Pharmaceuticals [Internet]. Madrigal pharmaceuticals announces FDA approval of Rezdiffra\u2122 (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. 2024 Available from: https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.049"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2015.10.008"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02410-x"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S367607"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.026"},{"key":"e_1_3_7_26_1","unstructured":"FDA [Internet]. Ozempic highlights of prescribing information. 2023. Available from: https:\/\/www.ozempic.com\/prescribing-information.html"},{"key":"e_1_3_7_27_1","unstructured":"FDA [Internet]. Saxenda highlights of prescribing information. 2023. Available from: https:\/\/www.novo-pi.com\/saxenda.pdf"},{"key":"e_1_3_7_28_1","unstructured":"FDA [Internet]. Trulicity highlights of prescribing information. 2022. Available from: https:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf"},{"key":"e_1_3_7_29_1","unstructured":"FDA [Internet]. Victoza highlights of prescribing information. 2023. Available from: https:\/\/www.novo-pi.com\/victoza.pdf"},{"key":"e_1_3_7_30_1","unstructured":"FDA [Internet]. Wegovy highlights of prescribing information 2024. Available from: https:\/\/www.novo-pi.com\/wegovy.pdf"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2656"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/10742484221146371"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2017.22.1.15"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23569"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071875"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_3_7_39_1","unstructured":"FDA [Internet]. Byetta highlights of prescribing information. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021773s043lbl.pdf"},{"key":"e_1_3_7_40_1","unstructured":"FDA [Internet]. Bydureon bcise highlights of prescribing information. 2023. Available from: https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/df5ddbd6-546b-43da-b794-56f711189aba\/df5ddbd6-546b-43da-b794-56f711189aba_viewable_rendition__v.pdf"},{"key":"e_1_3_7_41_1","unstructured":"FDA [Internet]. Adlyxin highlights of prescribing information. 2022. Available from: https:\/\/products.sanofi.us\/adlyxin\/adlyxin.pdf"},{"key":"e_1_3_7_42_1","unstructured":"FDA [Internet]. Rybelsus highlights of prescribing information. 2024. Available from: https:\/\/www.novo-pi.com\/rybelsus.pdf"},{"key":"e_1_3_7_43_1","unstructured":"FDA [Internet]. Mounjaro highlights of prescribing information. 2023. Available from: https:\/\/pi.lilly.com\/us\/mounjaro-uspi.pdf"},{"key":"e_1_3_7_44_1","unstructured":"FDA [Internet]. Zepbound highlights of prescribing information. 2024. Available from: https:\/\/pi.lilly.com\/us\/zepbound-uspi.pdf"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07105-9"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119324"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-043021-014919"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16794"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5573"},{"key":"e_1_3_7_50_1","unstructured":"Sa NP Kliers I L \u00d8 et al. Phase 3 ESSENCE trial: semaglutide in metabolic dysfunction-associated steatohepatitis (MASH). Oral presentation presented at: American Association For The Study Of Liver Diseases. San Diego. p. CA2024."},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.10.002"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14032"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.08.088"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084334"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.272"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30311-0"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.101117"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14765"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02666.x"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2009.05.1997"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2124"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1472-y"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1745"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22726"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2760"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1625"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2759"},{"key":"e_1_3_7_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60936-9"},{"key":"e_1_3_7_88_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2761"},{"key":"e_1_3_7_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60976-4"},{"key":"e_1_3_7_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12937"},{"key":"e_1_3_7_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30023-8"},{"key":"e_1_3_7_92_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1473"},{"key":"e_1_3_7_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13824"},{"key":"e_1_3_7_94_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"e_1_3_7_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12634"},{"key":"e_1_3_7_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14234"},{"key":"e_1_3_7_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-1012-6"},{"key":"e_1_3_7_98_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02685"},{"key":"e_1_3_7_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.12.001"},{"key":"e_1_3_7_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725"},{"key":"e_1_3_7_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.11.007"},{"key":"e_1_3_7_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14399"},{"key":"e_1_3_7_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073"},{"key":"e_1_3_7_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01226-y"},{"key":"e_1_3_7_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01575-9"},{"key":"e_1_3_7_106_1","unstructured":"FDA [Internet]. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. 2024 Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or"},{"key":"e_1_3_7_107_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_7_108_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_7_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_3_7_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_7_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5"},{"key":"e_1_3_7_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.032"},{"key":"e_1_3_7_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.08.038"},{"key":"e_1_3_7_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.07.008"},{"key":"e_1_3_7_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16608"},{"key":"e_1_3_7_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18331"},{"key":"e_1_3_7_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05265-7"},{"key":"e_1_3_7_118_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001556"},{"key":"e_1_3_7_119_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389203718666170428121647"},{"key":"e_1_3_7_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7"},{"key":"e_1_3_7_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.06.004"},{"key":"e_1_3_7_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.010"},{"key":"e_1_3_7_123_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1816152"},{"key":"e_1_3_7_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.52"},{"key":"e_1_3_7_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dms030"},{"key":"e_1_3_7_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02084-6"},{"key":"e_1_3_7_127_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463"},{"key":"e_1_3_7_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2022.01.008"},{"key":"e_1_3_7_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101370"},{"key":"e_1_3_7_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9"},{"key":"e_1_3_7_131_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2883"},{"key":"e_1_3_7_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30313-2"},{"key":"e_1_3_7_133_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1622"},{"key":"e_1_3_7_134_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad009"},{"key":"e_1_3_7_135_1","unstructured":"Novo Nordisk A\/S [Internet]. Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial. 2024 [cited 2024 Apr 2]. Available from: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=167028"},{"key":"e_1_3_7_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2023.07.008"},{"key":"e_1_3_7_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.11.037"},{"key":"e_1_3_7_138_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_3_7_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02526-x"},{"key":"e_1_3_7_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12268"},{"key":"e_1_3_7_141_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3673"},{"key":"e_1_3_7_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100525"},{"key":"e_1_3_7_143_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13553"},{"key":"e_1_3_7_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15083"},{"key":"e_1_3_7_145_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12624"},{"key":"e_1_3_7_146_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1063033"},{"key":"e_1_3_7_147_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2021.2002616"},{"key":"e_1_3_7_148_1","unstructured":"FDA [Internet]. Lantus (insulin glargine) highlights of prescribing information. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021081s078s079lbl.pdf"},{"key":"e_1_3_7_149_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01556-2"},{"key":"e_1_3_7_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102834"},{"key":"e_1_3_7_151_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000728"},{"key":"e_1_3_7_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.025"},{"key":"e_1_3_7_153_1","unstructured":"American Society of Anesthesiologists [Internet]. American society of anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. 2023 [cited 2024 Apr 2]. Available from: https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative"},{"key":"e_1_3_7_154_1","unstructured":"American Association for the Study of Liver Diseases [Internet]. GI multi-society statement regarding GLP-1 agonists and endoscopy. 2023. Available from: https:\/\/www.aasld.org\/news\/gi-multi-society-statement-regarding-glp-1-agonists-and-endoscopy"},{"key":"e_1_3_7_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.002"},{"key":"e_1_3_7_156_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.5003"},{"key":"e_1_3_7_157_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S004"},{"key":"e_1_3_7_158_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00836-9"},{"key":"e_1_3_7_159_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2040-1124.2010.00022.x"},{"key":"e_1_3_7_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.187"},{"key":"e_1_3_7_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156043"},{"key":"e_1_3_7_162_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735019"},{"key":"e_1_3_7_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171003"},{"key":"e_1_3_7_164_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0797"},{"key":"e_1_3_7_165_1","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2023.2184796"},{"key":"e_1_3_7_166_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01707-4"},{"key":"e_1_3_7_167_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05715-4"},{"key":"e_1_3_7_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00070-5"},{"key":"e_1_3_7_169_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_7_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_3_7_171_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w"},{"key":"e_1_3_7_172_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"e_1_3_7_173_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"e_1_3_7_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.013"},{"key":"e_1_3_7_175_1","unstructured":"Altimmune [Internet]. Altimmune announces positive topline results from 24-week (12-week extension) trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). 2022 [cited 2024 Apr 2]. Available from: https:\/\/ir.altimmune.com\/news-releases\/news-release-details\/altimmune-announces-positive-topline-results-24-week-12-week"},{"key":"e_1_3_7_176_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_3_7_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(24)00560-9"},{"key":"e_1_3_7_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107176"},{"key":"e_1_3_7_179_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972"},{"key":"e_1_3_7_180_1","unstructured":"American Diabetes Association [Internet]. American Diabetes Association highlights novel agent retatrutide which results in substantial weight reduction in people with obesity or type 2 diabetes during late breaking symposium. 2023 [cited 2024 Apr 2]. Available from: https:\/\/diabetes.org\/newsroom\/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium"},{"key":"e_1_3_7_181_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319104"},{"key":"e_1_3_7_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.03.041"},{"key":"e_1_3_7_183_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2208746"},{"key":"e_1_3_7_184_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v15.i8.1001"},{"key":"e_1_3_7_185_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.617400"},{"key":"e_1_3_7_186_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01425-3"},{"key":"e_1_3_7_187_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304286"},{"key":"e_1_3_7_188_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01163-7"},{"key":"e_1_3_7_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.034"},{"key":"e_1_3_7_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.003"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2025.2473062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T09:11:00Z","timestamp":1743757860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2025.2473062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":188,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,4]]}},"alternative-id":["10.1080\/13543784.2025.2473062"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2025.2473062","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}